ATRC

AtriCure, Inc. 10-Q Summary: Quarter Ended March 31, 2006

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for AtriCure, Inc., a Delaware corporation developing and selling surgical devices for the treatment of atrial fibrillation (AF). The reporting period covers the three months ended March 31, 2006. The Company's primary product is the AtriCure bipolar ablation system, which accounted for 85% of revenue in this period. The Company operates in a single segment with sales primarily in the United States and internationally through distributors and a wholly-owned European subsidiary.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 15.2% year-over-year, driven by an 11% increase in unit sales of disposable products and higher average selling prices.
• Improved Margins: Gross margin improved from 74% to 81%. Cost of revenue decreased 16.7% despite higher volume, attributed to a 25% reduction in average cost per unit following the acquisition of Enable Medical Corporation in late 2005.
• Increased Operating Expenses: Total operating expenses rose 49.4% to $10.4 million. Research and Development (R&D) expenses increased 67.6% due to hiring 21 new personnel and expanded clinical trials. Selling, General, and Administrative (SG&A) expenses increased 43.4% due to headcount growth and corporate expenditures.
• Elimination of Preferred Stock Interest: Preferred stock interest expense dropped to zero from $976,292 in the prior year following the conversion of preferred stock to common stock during the August 2005 IPO.
• Cash Position: Cash and cash equivalents decreased by $4.4 million during the quarter due to operating losses and investing activities, though the balance remains significantly higher than the prior year due to IPO proceeds.

Outlook, Risks, and Management Commentary

• Regulatory Status: Substantially all revenue is generated from the "off-label" use of the AtriCure bipolar ablation system for AF treatment. The system is not FDA-approved for this specific indication. The Company intends to seek FDA approval as early as 2009.
• Clinical Trials: The Company is conducting the RESTORE-SR clinical trial (226 patients required; 32 enrolled as of April 30, 2006) and the RESTORE-SR II feasibility study for minimally invasive sole-therapy (25 patients required; 21 treated as of May 5, 2006).
• Liquidity: Management believes current cash and investments (~$28 million) are sufficient to meet needs for at least the next 12 months. However, future funding may be required for clinical trials and operations if FDA approval is delayed.
• Legal Proceedings: The Company is involved in litigation with former European distributor Life Support Technology LST B.V. regarding distribution agreements and unpaid obligations. The Company intends to defend these suits vigorously.
• Accounting Changes: The Company adopted SFAS 123(R) on January 1, 2006, requiring fair value measurement of stock-based compensation. This resulted in $216,014 of stock-based compensation expense for the quarter.

Key Investor Verification Points

• Off-Label Revenue Dependency: Verify the sustainability of revenue streams given that the primary product is used off-label for its main indication (AF treatment) and lacks FDA approval for this use.
• Cash Burn Rate: Monitor the net cash used in operating activities ($3.8 million for the quarter) against the current cash balance to assess runway before potential dilution or debt financing is required.
• Clinical Trial Progress: Track enrollment and results of the RESTORE-SR and RESTORE-SR II trials, as FDA approval is critical for long-term market expansion and marketing capabilities.
• Legal Exposure: Assess the potential financial impact of the ongoing litigation with LST B.V. in the Netherlands and Ohio.
• Expense Trajectory: Evaluate whether the significant increase in R&D and SG&A expenses (up 49% YoY) can be sustained or if it will pressure profitability in future periods.